Zura Bio (ZURA) Projected to Post Earnings on Tuesday

Key Points

• Zura Bio is expected to announce its Q2 2025 earnings on August 12, anticipating a loss of ($0.19) per share.
• Bank of America raised its holdings in Zura Bio by 31.9% recently, indicating institutional investor interest as 61.14% of the stock is owned by institutional investors.
• Analysts maintain a consensus buy rating for Zura Bio, with a price target decrease from $19.00 to $17.00, and an average target of $14.33.

Zura Bio (NASDAQ:ZURA - Get Free Report) is projected to issue its Q2 2025 quarterly earnings data before the market opens on Tuesday, August 12th. Analysts expect Zura Bio to post earnings of ($0.19) per share for the quarter.

Zura Bio (NASDAQ:ZURA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.02). On average, analysts expect Zura Bio to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Zura Bio Trading Down 4.1%

NASDAQ ZURA traded down $0.06 on Friday, hitting $1.42. 232,648 shares of the company's stock traded hands, compared to its average volume of 873,455. The firm's 50-day moving average price is $1.32 and its two-hundred day moving average price is $1.33. Zura Bio has a 1-year low of $0.97 and a 1-year high of $5.07. The firm has a market capitalization of $97.10 million, a PE ratio of -2.03 and a beta of -0.06.

Analysts Set New Price Targets

Separately, Oppenheimer reduced their price target on shares of Zura Bio from $19.00 to $17.00 and set an "outperform" rating on the stock in a research report on Friday, May 9th. Seven equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $14.33.

Institutional Trading of Zura Bio

An institutional investor recently raised its position in Zura Bio stock. Bank of America Corp DE increased its stake in shares of Zura Bio Limited (NASDAQ:ZURA - Free Report) by 31.9% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 41,222 shares of the company's stock after buying an additional 9,966 shares during the quarter. Bank of America Corp DE owned about 0.06% of Zura Bio worth $103,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 61.14% of the company's stock.

Zura Bio Company Profile

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.